| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(19851215)56:12<2762::AID-CNCR2820561207>3.0.CO;2-E |
| P698 | PubMed publication ID | 4052950 |
| P2093 | author name string | Boyd JF | |
| Garcia JC | |||
| Geer MR | |||
| Friess GG | |||
| P2860 | cites work | Approaches to sudden death from coronary heart disease | Q34051584 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| P304 | page(s) | 2762-2764 | |
| P577 | publication date | 1985-12-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. | |
| P478 | volume | 56 |
| Q53756046 | Acute Cardiotoxicity After Daunorubicin in Acute Myeloid Leukaemia. |
| Q48549966 | Acute arrhythmogenicity of first-dose chemotherapeutic agents in children |
| Q38542462 | Anthracycline-Induced Cardiomyopathy in Adults |
| Q38025714 | Antineoplastic drug-induced bradyarrhythmias. |
| Q28322063 | Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring |
| Q34277031 | Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection |
| Q51039319 | Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. |
| Q67839954 | Early cardiac toxicity of 4′-iodo-4′-deoxydoxorubicin |
| Q33917116 | Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicity |
| Q44100282 | Effects of docosahexaenoic acid on [Ca(2+)](i) increase induced by doxorubicin in ventricular rat cardiomyocytes. |
| Q40355162 | Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment |
| Q34128868 | Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. |
| Q35827798 | PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer |
Search more.